Stock Markets Taper on High Valuations, Upcoming Election
In two weeks we potentially could see a number of prominent news items which could change the trajectory of stock market enthusiasm.
Danaher Corporation (DHR) Q3 2024 Earnings Call Transcript
Danaher Corporation (NYSE:DHR ) Q3 2024 Earnings Call Transcript October 22, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer Blair - President and CEO Matt McGrew - EVP and CFO Conference Call Participants Tycho Peterson - Jefferies Michael Ryskin - Bank of America Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Scott Davis - Melius Research Puneet Souda - Leerink Partners Dan Leonard - UBS Jack Meehan - Nephron Research Operator My name is Ashley and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation's Third Quarter 2024 Earnings Results Conference Call.
Danaher (DHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Danaher (DHR) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Danaher (DHR) Tops Q3 Earnings and Revenue Estimates
Danaher (DHR) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $2.02 per share a year ago.
Danaher beats quarterly profit estimates on strong demand for bioprocessing unit
Danaher on Tuesday beat Wall Street estimates for third-quarter profit on strong demand for its diagnostics and bioprocessing businesses, alongside growth in its molecular testing unit.
Exploring Analyst Estimates for Danaher (DHR) Q3 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Danaher (DHR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Danaher to Benefit From Business Strength Amid Headwinds
DHR stands to benefit from strength in the clinical diagnostics business, Abcam buyout and shareholder-friendly policies. Softness in the Instrument unit remains a concern.
Danaher Q3 Preview: Market Share Gains In Molecular Testing
I reiterate my 'Strong Buy' rating for Danaher, with a one-year price target of $310 per share, citing recovery in bioprocessing and market share gains in molecular testing. Danaher's bioprocessing market shows high-single-digit growth in orders, with stabilization in China, and is expected to sustain recovery in Q3 and FY25. Cepheid's market share gains in molecular testing, including FDA authorization for its Hepatitis C RNA test, highlight Danaher's innovation and growth potential.
Here's Why It is Appropriate to Retain Danaher Stock For Now
DHR benefits from solid momentum across its Diagnostics segment. However, increasing expenses remain a concern.
Danaher: Lofty Price, Bright Future
Danaher's high valuation and flat 2024 EPS growth might raise eyebrows, but its track record, strategic acquisitions, and long-term growth potential make it a solid buy for those who can. Despite trading at a premium, Danaher's strong history, efficient operations, and potential for double-digit EPS growth in 2025 make it one of the few stocks I'm buying at a lofty price. Danaher's blend of strategic acquisitions and operational efficiency makes it a long-term winner. I'm adding to my position despite the high P/E, expecting strong returns as growth picks up.
Why Is Danaher (DHR) Up 2% Since Last Earnings Report?
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
